128625-52-5
[1]SyntheticCommunications,2005,vol.35,p.2265-2270
[1]Shpiro,Natalia;Marquez,Rodolfo[SyntheticCommunications,2005,vol.35,#17,p.2265-2270]
[2]Barrett,StephenD.;Bridges,AlexanderJ.;Dudley,DavidT.;Saltiel,AlanR.;Fergus,JamesH.;Flamme,CathlinM.;Delaney,AmyM.;Kaufman,Michael;LePage,Sophie;Leopold,WilburR.;Przybranowski,SallyA.;Sebolt-Leopold,Judith;VanBecelaere,Keri;Doherty,AnnetteM.;Kennedy,RobertM.;Marston,Dan;HowardJr.,W.Allen;Smith,Yvonne;Warmus,JosephS.;Tecle,Haile[BioorganicandMedicinalChemistryLetters,2008,vol.18,#24,p.6501-6504]
[3]Hamza,Hazem;Koch-Heier,Julia;Laure,Martin;Ludwig,Stephan;Planz,Oliver;Pleschka,Stephan;Quernheim,Martin;Schreiber,Andre;Müller,Christin;Müller,Gerhard[AntiviralResearch,2020,vol.178]
[1]Shpiro,Natalia;Marquez,Rodolfo[SyntheticCommunications,2005,vol.35,#17,p.2265-2270]
[1]Shpiro,Natalia;Marquez,Rodolfo[SyntheticCommunications,2005,vol.35,#17,p.2265-2270]
Title: Pyrethroid Insecticide Cypermethrin Modulates Gonadotropin Synthesis via Calcium Homeostasis and ERK1/2 Signaling in LβT2 Mouse Pituitary Cells.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20180301
Title: Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells.
Journal: Toxicology 20171201
Title: Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways.
Journal: Toxicology in vitro : an international journal published in association with BIBRA 20170401
Title: Endoplasmic Reticulum Stress Induction and ERK1/2 Activation Contribute to Nefazodone-Induced Toxicity in Hepatic Cells.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20161201
Title: Hydroxyflutamide affects connexin 43 via the activation of PI3K/Akt-dependent pathway but has no effect on the crosstalk between PI3K/Akt and ERK1/2 pathways at the Raf-1 kinase level in primary rat Sertoli cells.
Journal: Toxicology in vitro : an international journal published in association with BIBRA 20160301
Title: U0126, a mitogen-activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up-regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells.
Journal: Archives of toxicology 20141201
Title: Endocrine disrupting effects of dichlorodiphenyltrichloroethane analogues on gonadotropin hormones in pituitary gonadotrope cells.
Journal: Environmental toxicology and pharmacology 20140501
Title: Pau d'arco activates Nrf2-dependent gene expression via the MEK/ERK-pathway.
Journal: The Journal of toxicological sciences 20140401
Title: Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20140201
Title: Cadmium induces N-cadherin cleavage via ERK-mediated γ-secretase activation in C6 astroglia cells.
Journal: Toxicology letters 20131024
Title: Flavanoids induce expression of the suppressor of cytokine signalling 3 (SOCS3) gene and suppress IL-6-activated signal transducer and activator of transcription 3 (STAT3) activation in vascular endothelial cells.
Journal: The Biochemical journal 20130901
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Inhibition of MEK pathway in vestibular schwannoma cell culture.
Journal: The Laryngoscope 20121001
Title: Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Journal: Bioscience reports 20120801
Title: Morphine activates the E twenty six-like transcription factor-1/serum response factor pathway via extracellular signal-regulated kinases 1/2 in F11 cells derived from dorsal root ganglia neurons.
Journal: The Journal of pharmacology and experimental therapeutics 20120701
Title: Phosphorylation of serine 21 modulates the proliferation inhibitory more than the differentiation inducing effects of C/EBPα in K562 cells.
Journal: Journal of cellular biochemistry 20120501
Title: MEK/Erk-based negative feedback mechanism involved in control of Steel Factor-triggered production of Krüppel-like factor 2 in mast cells.
Journal: Cellular signalling 20120401
Title: 3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization.
Journal: European journal of medicinal chemistry 20120101
Title: Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Journal: Cancer cell 20111213
Title: Comprehensive analysis of kinase inhibitor selectivity.
Journal: Nature biotechnology 20111030
Title: ERK1/2 and ERK5 have distinct roles in the regulation of brain-derived neurotrophic factor expression.
Journal: Journal of neuroscience research 20111001
Title: Cigarette smoke components induce matrix metalloproteinase-1 in aortic endothelial cells through inhibition of mTOR signaling.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20111001
Title: Epidermal growth factor induces matrix metalloproteinase-1 (MMP-1) expression and invasion in glioma cell lines via the MAPK pathway.
Journal: Journal of neuro-oncology 20110901
Title: Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells.
Journal: American journal of physiology. Cell physiology 20110901
Title: BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
Journal: International journal of oncology 20110901
Title: Compartmentalization of the MAPK scaffold protein KSR1 modulates synaptic plasticity in hippocampal neurons.
Journal: FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20110701
Title: The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells.
Journal: Leukemia 20110701
Title: Mitogen-activated protein kinase kinase 1 (MEK1) stabilizes MyoD through direct phosphorylation at tyrosine 156 during myogenic differentiation.
Journal: The Journal of biological chemistry 20110527
Title: Coordinated waves of gene expression during neuronal differentiation of embryonic stem cells as basis for novel approaches to developmental neurotoxicity testing.
Journal: Cell death and differentiation 20110301
Title: ERK5 signalling in prostate cancer promotes an invasive phenotype.
Journal: British journal of cancer 20110215
Title: Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.
Journal: Breast cancer research : BCR 20110101
Title: Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Journal: Chemistry & biology 20101124
Title: MEK inhibitors suppress beta-amyloid production by altering the level of a beta-C-terminal fragment of amyloid precursor protein in neuronal cells.
Journal: FEBS letters 20100804
Title: Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways.
Journal: Bioorganic & medicinal chemistry letters 20100801
Title: Regulation of the miR-212/132 locus by MSK1 and CREB in response to neurotrophins.
Journal: The Biochemical journal 20100513
Title: Three inhibitors of FGF receptor, ERK, and GSK3 establishes germline-competent embryonic stem cells of C57BL/6N mouse strain with high efficiency and stability.
Journal: Genesis (New York, N.Y. : 2000) 20100501
Title: Hepatitis C virus RNA replication is regulated by Ras-Erk signalling.
Journal: The Journal of general virology 20100301
Title: Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors.
Journal: The Journal of pharmacology and experimental therapeutics 20100301
Title: Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.
Journal: Leukemia research 20100301
Title: Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100215
Title: Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.
Journal: Breast cancer research and treatment 20100201
Title: Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib.
Journal: Biochemical and biophysical research communications 20100122
Title: Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK.
Journal: Arteriosclerosis, thrombosis, and vascular biology 20091101
Title: MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM.
Journal: Leukemia 20091001
Title: Suppression of Erk signalling promotes ground state pluripotency in the mouse embryo.
Journal: Development (Cambridge, England) 20091001
Title: Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.
Journal: Nature 20090917
Title: Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090915
Title: Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.
Journal: Thyroid : official journal of the American Thyroid Association 20090801
Title: Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation.
Journal: Cancer research 20090601
Title: Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040.
Journal: Archives of otolaryngology--head & neck surgery 20090401
Title: Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma.
Journal: Cancer research 20090301
Title: LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.
Journal: British journal of cancer 20090127
Title: The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.
Journal: Bioorganic & medicinal chemistry letters 20081215
Title: 2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase).
Journal: Bioorganic & medicinal chemistry letters 20081201
Title: Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.
Journal: Blood 20080915
Title: Reduction of chronic allograft nephropathy by inhibition of extracellular signal-regulated kinase 1 and 2 signaling.
Journal: American journal of physiology. Renal physiology 20080901
Title: Cellular energetic status supervises the synthesis of bis-diphosphoinositol tetrakisphosphate independently of AMP-activated protein kinase.
Journal: Molecular pharmacology 20080801
Title: Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Journal: The Prostate 20080615
Title: Increase of MCP-1 (CCL2) in myelin mutant Schwann cells is mediated by MEK-ERK signaling pathway.
Journal: Glia 20080601
Title: K-ras as a target for lung cancer therapy.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080601
Title: The ground state of embryonic stem cell self-renewal.
Journal: Nature 20080522
Title: Enzyme kinetics and binding studies on inhibitors of MEK protein kinase.
Journal: Biochemistry 20080429
Title: Pharmacophore identification of Raf-1 kinase inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20080401
Title: The selectivity of protein kinase inhibitors: a further update.
Journal: The Biochemical journal 20071215
Title: Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
Journal: The Journal of clinical endocrinology and metabolism 20071201
Title: PD184352 releases the regular hypoxic reversible DNA replication arrest in T24 cells.
Journal: Journal of biochemistry and molecular biology 20071130
Title: 4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.
Journal: Journal of medicinal chemistry 20071018
Title: Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms.
Journal: Arthritis and rheumatism 20071001
Title: MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
Journal: Blood 20070915
Title: Requirement for ERK MAP kinase in mouse preimplantation development.
Journal: Development (Cambridge, England) 20070801
Title: Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1.
Journal: Oncogene 20070607
Title: Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Journal: Cancer research 20070515
Title: MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Journal: Blood 20070501
Title: ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signaling in human proximal tubular cells.
Journal: Journal of cellular physiology 20070401
Title: Inhibition of the MAP kinase activity suppresses estrogen-induced breast tumor growth both in vitro and in vivo.
Journal: International journal of oncology 20070401
Title: MEK blockade converts AML differentiating response to retinoids into extensive apoptosis.
Journal: Blood 20070301
Title: Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer.
Journal: Molecular cancer therapeutics 20070301
Title: Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells.
Journal: Urology 20070301
Title: Lovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts.
Journal: The Biochemical journal 20070101
Title: The INT6 cancer gene and MEK signaling pathways converge during zebrafish development.
Journal: PloS one 20070101
Title: Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells.
Journal: Molecular pharmacology 20061201
Title: A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.
Journal: Cancer research 20061201
Title: Protein kinases as drug targets in cancer.
Journal: Current cancer drug targets 20061101
Title: MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo.
Journal: Cancer biology & therapy 20061001
Title: New molecular targeted therapies in thyroid cancer.
Journal: Anti-cancer drugs 20060901
Title: An in vivo platform for translational drug development in pancreatic cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20060801
Title: Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.
Journal: Molecular cancer therapeutics 20060701
Title: MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis.
Journal: Blood 20060601
Title: Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease.
Journal: Journal of the American Society of Nephrology : JASN 20060601
Title: Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20060401
Title: Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
Journal: Breast cancer research and treatment 20060301
Title: Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death.
Journal: Biochemical and biophysical research communications 20060127
Title: BRAF mutation predicts sensitivity to MEK inhibition.
Journal: Nature 20060119
Title: The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines.
Journal: The Journal of pharmacology and experimental therapeutics 20060101
Title: Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells.
Journal: Cancer research 20051101
Title: Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth.
Journal: Cancer biology & therapy 20051101
Title: Two targets are better than one. Promising combination therapy to treat breast cancer.
Journal: Cancer biology & therapy 20051101
Title: ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells.
Journal: Oncogene 20051013
Title: Anticancer Drug Discovery and Development - SRI's Seventh Annual Summit.
Journal: IDrugs : the investigational drugs journal 20051001
Title: Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia.
Journal: Leukemia 20050901
Title: Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.
Journal: Leukemia 20050901
Title: Activation of mitogen-activated protein kinase is required for migration and invasion of placental site trophoblastic tumor.
Journal: The American journal of pathology 20050901
Title: Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050810
Title: Treating cancer by blocking cell signals.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050810
Title: Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
Journal: Cancer research 20050401
Title: A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.
Journal: Neoplasia (New York, N.Y.) 20050401
Title: Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.
Journal: Cancer research 20050301
Title: ERK kinase inhibition stabilizes the aryl hydrocarbon receptor: implications for transcriptional activation and protein degradation.
Journal: The Journal of biological chemistry 20050211
Title: Increased dissolution rate and bioavailability through comicronization with microcrystalline cellulose.
Journal: Pharmaceutical development and technology 20050101
Title: Identification of filamin C as a new physiological substrate of PKBalpha using KESTREL.
Journal: The Biochemical journal 20041215
Title: Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041115
Title: Molecular cross-talk between MEK1/2 and mTOR signaling during recovery of 293 cells from hypertonic stress.
Journal: The Journal of biological chemistry 20041029
Title: In vitro and in vivo metabolism of the anti-cancer agent CI-1040, a MEK inhibitor, in rat, monkey, and human.
Journal: Pharmaceutical research 20040901
Title: Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells.
Journal: Molecular cancer therapeutics 20040801
Title: Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells.
Journal: Blood 20040715
Title: Stress- and mitogen-induced phosphorylation of the synapse-associated protein SAP90/PSD-95 by activation of SAPK3/p38gamma and ERK1/ERK2.
Journal: The Biochemical journal 20040515
Title: Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure.
Journal: BMC cancer 20040101
Title: Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro.
Journal: The Journal of biological chemistry 20031121
Title: Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha.
Journal: The EMBO journal 20031103
Title: CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).
Journal: Seminars in oncology 20031001
Title: Synthesis and evaluation of 4-anilino-6,7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade.
Journal: Bioorganic & medicinal chemistry letters 20030915
Title: Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade.
Journal: Cancer research 20030915
Title: Effects of the MEK inhibitor CI-1040 (PD 184352) on progenitor growth from normal and myelodysplastic marrow.
Journal: Haematologica 20030901
Title: Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44.
Journal: Biochemical and biophysical research communications 20030516
Title: Chronic activation of extracellular-signal-regulated protein kinases by phenylephrine is required to elicit a hypertrophic response in cardiac myocytes.
Journal: The Biochemical journal 20030401
Title: Proliferation of cancer cells despite CDK2 inhibition.
Journal: Cancer cell 20030301
Title: A conserved role for the MEK signalling pathway in neural tissue specification and posteriorisation in the invertebrate chordate, the ascidian Ciona intestinalis.
Journal: Development (Cambridge, England) 20030101
Title: Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
Journal: Blood 20021101
Title: Ras/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes.
Journal: Circulation research 20021101
Title: Targeting intracellular signal transduction. A new paradigm for a brave new world of molecularly targeted therapeutics.
Journal: Hematology/oncology clinics of North America 20021001
Title: Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1.
Journal: The Biochemical journal 20020901
Title: Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia.
Journal: Blood 20020501
Title: Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Journal: Cancer research 20020101
Title: Agents targeting ras signaling pathway.
Journal: Current pharmaceutical design 20020101
Title: Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571.
Journal: Cancer biology & therapy 20020101
Title: Beyond directed therapeutics--are two drugs always better than one?
Journal: Cancer biology & therapy 20020101
Title: Suppression of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated CYP1A1 and CYP1B1 induction by 12-O-tetradecanoylphorbol-13-acetate: role of transforming growth factor beta and mitogen-activated protein kinases.
Journal: Biochemical pharmacology 20011201
Title: Antagonistic effects of phorbol esters on insulin regulation of insulin-like growth factor-binding protein-1 (IGFBP-1) but not glucose-6-phosphatase gene expression.
Journal: The Biochemical journal 20011101
Title: Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.
Journal: The Journal of clinical investigation 20010915
Title: MEK1/2 inhibitors promote Ara-C-induced apoptosis but not loss of Deltapsi(m) in HL-60 cells.
Journal: Biochemical and biophysical research communications 20010907
Title: Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway.
Journal: FEBS letters 20010727
Title: Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.
Journal: Cancer research 20010701
Title: Role of the ERK pathway in the activation of store-mediated calcium entry in human platelets.
Journal: The Journal of biological chemistry 20010511
Title: Specificity and mechanism of action of some commonly used protein kinase inhibitors.
Journal: The Biochemical journal 20001001
Title: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo.
Journal: Nature medicine 19990701
Title: Allen LF, et al. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol. 2003 Oct;30(5 Suppl 16):105-16.
Title: Wei CR, et al. MEK inhibitor CI-1040 induces apoptosis in acute myeloid leukemia cells in vitro. Eur Rev Med Pharmacol Sci. 2016 May;20(10):1961-8.
Title: Kramer BW, et al. Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040strongly reduces growth and improves lung structure. BMC Cancer. 2004 Jun 1;4:24.
